Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity.
Harada Y, Takahashi H, Fujimoto T, Horikoshi F, Chida S, Tanaka K, Minari K, Tanimoto Y, Fujisaki S, Miura H, Nakauchi M, Shimasaki N, Suzuki Y, Arita T, Hamamoto I, Yamamoto N, Hasegawa H, Odagiri T, Tashiro M, Nobusawa E.
Harada Y, et al. Among authors: yamamoto n.
Vaccine. 2024 Oct 3;42(23):126242. doi: 10.1016/j.vaccine.2024.126242. Epub 2024 Aug 29.
Vaccine. 2024.
PMID: 39213922